Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18353218 | 0.86 | GABRA1 (0.39) | GABRA1GABRB1LMNAP2RX3P2RX2 | |
| SCHEMBL23970881 | 0.86 | GABRA1 (0.39) | GABRA1GABRB1LMNAP2RX3P2RX2 | |
| SCHEMBL13362528 | 0.82 | LMNA (0.44) | GABRA1GABRB1LMNASMN1; SMN2 | |
| SCHEMBL18068021 | 0.80 | GABRA1 (0.35) | GABRA1GABRB1LMNAP2RX3P2RX2 | |
| SCHEMBL22299273 | 0.80 | LMNA (0.39) | GABRA1GABRB1LMNAP2RX3P2RX2 | |
| SCHEMBL2738317 | 0.80 | LMNA (0.40) | GABRA1GABRB1LMNASMN1; SMN2 | |
| SCHEMBL18068022 | 0.80 | GABRA1 (0.35) | GABRA1GABRB1LMNAP2RX3P2RX2 | |
| SCHEMBL18488035 | 0.78 | AAK1 (0.36) | GABRA1GABRB1LMNAP2RX3P2RX2 | |
| SCHEMBL20844146 | 0.78 | AAK1 (0.34) | GABRA1GABRB1LMNAP2RX3P2RX2 | |
| SCHEMBL12305596 | 0.78 | GABRA1 (0.34) | GABRA1GABRB1LMNAP2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002364-A1 | BENZOTHIOPHENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-9957275-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170190708-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20160130275-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2016-05-12 | — | — | US | disclosed |
| US-9238039-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20140154240-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2014-06-05 | — | — | US | disclosed |
| US-8486938-B2 | Pyrazolo[1,5-a]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140154240-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | GABRA1 3889/4885GABRB1 4379/4885LMNA 3626/4885 |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | GABRA1 3889/4885GABRB1 4379/4885LMNA 3626/4885 |
| US-20170190708-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | GABRA1 3889/4885GABRB1 4379/4885LMNA 3626/4885 |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | GABRA1 3889/4885GABRB1 4379/4885LMNA 3626/4885 |
| US-20160130275-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | GABRA1 3889/4885GABRB1 4379/4885LMNA 3626/4885 |
| US-20230002364-A1 | BENZOTHIOPHENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | GPER1, GABRQ, GPR39 | GABRA1 29/4885GABRB1 17/4885LMNA 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.